Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research & Development & Chief Scientific ...
November 02 2020 - 5:58AM
Business Wire
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that
Karin Rosén, M.D., Ph.D., has joined the company as executive vice
president, research and development and chief scientific officer,
reporting directly to Tim Walbert, chairman, president and chief
executive officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201102005247/en/
Karin Rosén, M.D., Ph.D. (Photo: Business
Wire)
“We are thrilled to welcome Karin to Horizon during this
transformative time in our company’s growth,” said Walbert. “We
have made significant progress during the last three years in
building a strong R&D organization and a diversified pipeline.
We are confident that Karin’s ability to build and lead
cross-functional teams, clinical development experience and
therapeutic area expertise, will contribute to solidifying our
position as a leading rare disease biopharmaceutical company.”
Dr. Rosén is an accomplished life sciences executive and
physician with nearly three decades of experience that includes
directing biologic clinical research and development and building,
leading and successfully launching multiple novel medicines in the
United States and globally. Prior to Horizon, she was senior vice
president, U.S. medical affairs at GlaxoSmithKline, where she led a
team of more than 300 physicians and medical professionals in
disease areas including immunology, respiratory and
inflammation.
“I have focused my entire career on collaborating with diverse
teams to address complex scientific problems that result in
treatments for patients in need,” said Dr. Rosén. “There is much
work to be done in the research and development of medicines for
rare diseases and I applaud Horizon’s continued commitment to this
space. The company’s evolution during the last decade to bring
therapies to the most underserved communities is inspiring and I
look forward to leading this accomplished R&D
organization.”
Prior to GlaxoSmithKline, Dr. Rosén was senior vice president,
U.S. and global medical affairs at Aimmune Therapeutics, Inc. as
well as a member of the clinical development leadership team
working on the Phase 2b-3/4 clinical programs and U.S. FDA and
European Medicines Agency filing strategies. Prior to Aimmune, Dr.
Rosén was therapeutic area head, immunology, at Genentech, a member
of the Roche Group. During her tenure at Genentech, she also served
as lead medical director responsible for developing Phase 2-3
clinical programs for multiple biologics in the areas of
immunology, respiratory, allergy and dermatology.
Dr. Rosén received her medical degree and doctorate from Lund
University in Lund, Sweden.
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com and follow us on Twitter,
LinkedIn, Instagram and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005247/en/
U.S. Media Contact: Geoff Curtis Executive Vice
President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024